Clinical trials: Vaccine Prophylaxis
Rabies
Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)
This study investigates the safety and immunogenicity (non-inferiority) of a Purified Chick Embryo Cell Vaccine (PCECV) administered in two different schedules (conventional versus abbreviated schedule) in healthy adults 18 to 50…
- Trial name
- NCT00825305
- Testing
- Abbreviated Zagreb 2-1-1 schedule, Standard Essen 1-1-1-1-1 schedule
- Where
- China
- Volunteers
- 825 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Prevention of Meningococcus C Infections
Evaluation of Vaccinal and Natural Immunity Against Meningococcus C
Meningococcus C vaccine was first used in France to prevent epidemics. It was a success in Puy-de-Dôme, Landes, Pyrénées Atlantiques and Hautes Pyrénées.
- Trial name
- NCT02844088
- Testing
- Meningococcus C conjugate vaccine
- Where
- France
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Influenza
Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines
The purpose of this study is to compare two licensed influenza vaccines (Fluzone and Fluarix) in terms of the immune response elicited and the safety/ any symptoms that may occur for up to six months after vaccination.
- Trial name
- NCT00197288
- Testing
- Influenza
- Where
- 15 sites in United States
- Volunteers
- 1,847 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Smallpox
A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects
The primary objective of this study is to evaluate the immune response after a single vaccination of pre-immune subjects compared to two vaccinations in naive subjects.
- Trial name
- NCT00316524
- Testing
- MVA-BN® (IMVAMUNE)
- Where
- Germany
- Volunteers
- 745 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Rabies
A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects
The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) or placebo in combination with rabies vaccine in…
- Trial name
- NCT00656097
- Testing
- CL184, HRIG
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases
Culturally Tailored HPV Psychoeducational Multimedia Intervention
Community members ages 18 - 45 years old from the El Paso, Texas, U.S.-Mexico Border Region will be recruited to compare psychoeducational multimedia interventions focused on the human papillomavirus (HPV).
- Conditions
- Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
- Trial name
- NCT06098690
- Testing
- Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
Influenza
A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine
This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using a new strain recommended for the 2008-2009 influenza season not previously contained in the trivalent intranasal…
- Trial name
- MI-MA182 (NCT00677820)
- Testing
- Trivalent influenza virus vaccine
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Herpes Zoster
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
The purpose of this study is to determine whether the investigational zoster vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile when given concomitantly with another…
- Trial name
- NCT00231816
- Testing
- ZOSTAVAX™ (concomitant), Comparator: Influenza Vaccine, ZOSTAVAX™ (Nonconcomitant)
- Volunteers
- 763 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198063
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents
This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety…
- Trial name
- NCT04992208
- Testing
- Experimental Group
- Where
- China
- Volunteers
- 31,041 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Prevention of Ebola Infection
Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)
The study evaluated the safety and immunogenicity of 3 consistency lots and a high-dose lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in healthy adults.
- Trial name
- NCT02503202
- Testing
- V920 Consistency Lot A, V920 Consistency Lot B, V920 Consistency Lot C
- Volunteers
- 1,197 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV/AIDS and Infections
Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda
The aim of this study is to compare the effectiveness of two vaccination strategies against Hepatitis B virus (HBV) in subjects already infected with human immunodeficiency virus (HIV).
- Trial name
- NCT02316444
- Testing
- Hepatitis B vaccine
- Where
- Uganda
- Volunteers
- 132 people
- Sponsor
- Fred Hutchinson Cancer Center
Lynch Syndrome
Preventive Dendritic Cell Vaccination for Lynch Syndrome
The aim of this study is to assess safety, immunogenicity and feasibility of vaccination with neopeptide-loaded dendritic cells in Lynch Syndrome subjects who are known to be carrier of a germline MMR-gene mutation without signs…
- Trial name
- PREVENT-Lynch (NCT07412197)
- Testing
- DC vaccination
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Radboud University Medical Center
Prophylaxis: Influenza
Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects
The purpose of this study is to evaluate the immunologic equivalence of three consecutive lots of a cell based trivalent subunit influenza vaccine (TIVc), and to assess immunogenicity, safety and tolerability of the vaccine and…
- Trial name
- NCT02256488
- Testing
- TIVc_LOT A, TIVc_LOT B, TIVc_LOT C
- Where
- 24 sites in United States
- Volunteers
- 1,561 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Prevention of Meningococcal Disease
Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents
The purpose of this study is to evaluate the safety and immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in comparison to licensed meningococcal polysaccharide vaccine administered to healthy adolescents ages 11 to…
- Trial name
- NCT00262041
- Testing
- MenACWY-CRM conjugate vaccine, adjuvanted, MenACWY-CRM conjugate vaccine, unadjuvanted, MenACWY polysaccharide vaccine
- Where
- 3 sites in United States
- Volunteers
- 524 people
- Sponsor
- Novartis Vaccines
Prophylaxis of Ross River Virus Infection
Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801
The purpose of this study is to verify the long-term safety of a 2.5 µg, adjuvanted (aluminium hydroxide) dose of Ross River Virus (RRV) vaccine.
- Trial name
- NCT01604746
- Testing
- Ross River Virus (RRV) Vaccine
- Where
- 13 sites in Australia
- Volunteers
- 1,146 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Prevention of : Herpes-Zoster
Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)
Primary objective: Immunogenicity To demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month schedule or as a 0-3 month…
- Trial name
- NCT00561080
- Testing
- Zostavax
- Volunteers
- 759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Dengue Fever
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00094705
- Testing
- rDEN2/4delta30(ME) Vaccine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B
Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator
This study will look at what happens to the level of protection against hepatitis B (HB) disease if a 'helper' gel is applied to the skin over the injection site of a small dose of hepatitis B vaccine.
- Trial name
- NCT00175435
- Testing
- Resiquimod gel
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Meningococcal Infections
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules
Primary :1.To demonstrate a sufficient immune response of rMenB+OMV NZ, when given concomitantly with routine infant vaccines to healthy infants at 2, 4 and 6 and 2, 3 and 4 months of age, as measured by percentage of subjects…
- Trial name
- NCT00721396
- Testing
- rMenB+OMV NZ, combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine, Pneumococcal vaccine
- Where
- 60 sites in Belgium, Czechia and 4 more
- Volunteers
- 1,885 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines